1. Home
  2. FEMY vs YFOR Comparison

FEMY vs YFOR Comparison

Compare FEMY & YFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FEMY

Femasys Inc.

HOLD

Current Price

$2.59

Market Cap

22.4M

Sector

Health Care

ML Signal

HOLD

YFOR

YYForce Inc. Class A Ordinary Shares

N/A

Current Price

$1.64

Market Cap

18.4M

ML Signal

N/A

Company Overview

Basic Information
Metric
FEMY
YFOR
Founded
2004
N/A
Country
United States
Singapore
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Professional Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
22.4M
18.4M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
FEMY
YFOR
Price
$2.59
$1.64
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$5.50
N/A
AVG Volume (30 Days)
173.5K
466.5K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
44.71
N/A
EPS
N/A
N/A
Revenue
$2,293,313.00
N/A
Revenue This Year
$105.16
N/A
Revenue Next Year
$200.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.77
N/A
52 Week Low
$0.29
$1.22
52 Week High
$6.29
$2.05

Technical Indicators

Market Signals
Indicator
FEMY
YFOR
Relative Strength Index (RSI) 42.01 68.29
Support Level $0.41 $1.22
Resistance Level $3.33 N/A
Average True Range (ATR) 0.23 0.19
MACD -0.04 0.04
Stochastic Oscillator 10.10 55.53

Price Performance

Historical Comparison
FEMY
YFOR

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: